Regeneron Pharmaceuticals
REGN
Market cap $61.3B

567.74 USD

+7.98

1.43%

At close Jul 11, 4:00 PM EDT

After hours

567.75

+0.01

0.00%

1 day

1.43%

5 days

3.98%

1 month

9.48%

3 months

2.45%

6 months

-20.81%

Year to date

-20.62%

1 year

-47.44%

5 years

-7.82%

10 years

5.88%

About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Employees: 15,158

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 15 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

15% more repeat investments, than reductions

Existing positions increased: 512 | Existing positions reduced: 446

7% more funds holding in top 10

Funds holding in top 10: 14 [Q4 2024] → 15 (+1) [Q1 2025]

1.0% less ownership

Funds ownership: 86.11% [Q4 2024] → 85.11% (-1.0%) [Q1 2025]

3% less call options, than puts

Call options by funds: $974M | Put options by funds: $1B

6% less first-time investments, than exits

New positions opened: 138 | Existing positions closed: 147

3% less funds holding

Funds holding: 1,296 [Q4 2024] → 1,263 (-33) [Q1 2025]

13% less capital invested

Capital invested by funds: $66.3B [Q4 2024] → $58B (-$8.34B) [Q1 2025]

See Fund Rankings

Research analyst outlook

15 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$547

4%

downside

Avg. target

$736

30%

upside

High target

$943

66%

upside

15 analyst ratings

11 positive

73%

3 neutral

20%

1 negative

7%

UBS Trung Huynh	3%upside $584	Neutral Maintained	11 Jul 2025
Morgan Stanley Matthew Harrison	33%upside $754	Overweight Maintained	10 Jul 2025
JP Morgan Chris Schott	41%upside $800	Overweight Maintained	9 Jun 2025
Citigroup Geoff Meacham	14%upside $650	Buy Maintained	2 Jun 2025
BMO Capital Evan David Seigerman	6%upside $600	Outperform Maintained	2 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 21 articles about REGN published over the past 30 days

Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025

Regeneron Pharmaceuticals, Inc.'s stock continues to remain in the accumulation phase even after the setbacks associated primarily with itepekimab and Eylea. At the same time, Dupixent will remain Regeneron's key "cash cow" and its savior, the profit from sales of which will rise sharply in 2027. From its oncology franchise, I highlight Lynozyfic, which received its first FDA approval on July 2, and Libtayo, whose sales reached $285 million in Q1 2025.

Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025

The Motley Fool

2 Beaten-Down Stocks to Buy and Hold

Equity markets have been volatile throughout the year. We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

2 Beaten-Down Stocks to Buy and Hold

Zacks Investment Research

FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.

FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.

Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment

US FDA approves Regeneron's blood cancer therapy

The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, providing another treatment option for patients with a recurring and common form of blood cancer.

US FDA approves Regeneron's blood cancer therapy

Zacks Investment Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade

Regeneron Pharmaceuticals, Inc. faces declining Eylea sales due to competition from Roche's Vabysmo and biosimilars like Amgen's Pavblu, but Dupixent's strong growth and new indications provide a robust near-term revenue driver. Libtayo and the oncology pipeline offer potential, but face tough competition and are unlikely to become blockbuster catalysts in the short term. The company's move into obesity drugs is a favorable development, with considerable potential from its experimental drug Trevogrumab, which shows promise in early trial data.

Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

CNBC Television

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

See News Rankings

Charts implemented using Lightweight Charts™